HDL and CETP in atherogenesis;HDL im Rahmen der Atherogenese und HDL-Steigerung durch CETP-Inhibition

Deutsche Medizinische Wochenschrift

Volumn 135, Issue 5, 2010, Pages 188-192

  Poss J ^a   Bohm M ^a   Laufs, U ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

CETP; HDL; Lipid metabolism; Statins

Indexed keywords

2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; ANACETRAPIB; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; PROTECTIVE AGENT; TORCETRAPIB; CLOFIBRIC ACID; DALCETRAPIB; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID DERIVATIVE; OXAZOLIDINONE DERIVATIVE; QUINOLINE DERIVATIVE; THIOL DERIVATIVE;

ATHEROGENESIS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CHOLESTEROL TRANSPORT; INFLAMMATION; LIPID BLOOD LEVEL; PATHOPHYSIOLOGY; REVIEW; ATHEROSCLEROSIS; BLOOD; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; DRUG ANTAGONISM; HUMAN; LIFESTYLE; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CLOFIBRIC ACID; CORONARY ARTERY DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIFE STYLE; NICOTINIC ACIDS; OXAZOLIDINONES; QUINOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SULFHYDRYL COMPOUNDS; TREATMENT OUTCOME;

EID: 77249163858     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0030-1247862     Document Type: Review

References (45)

1. Clofibrate and niacin in coronary heart disease. JAMA 1975 231 360-381
2. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002 106 3143-3421
3. Assmann G, Schulte H. The Prospective Cardiovascular Munster (PROCAM) study: prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. Am Heart J 1988 116 1713-1724
4. Barter P J., Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007 357 2109-2122
5. Bloomfield D, Carlson G L., Sapre A, et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart J 2009 157 352-360 e352
6. Bots M L., Visseren F L., Evans G W., et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 2007 370 153-160
7. Briel M, Ferreira-Gonzalez I, You J J., et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ 2009 338 b92-b92
8. Brousseau M E., Schaefer E J., Wolfe M L., et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004 350 1505-1515
9. Brown B G., Zhao X Q., Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001 345 1583-1592
10. Canner P L., Berge K G., Wenger N K., et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986 8 1245-1255
11. Clark R W., Ruggeri R B., Cunningham D, Bamberger M J. Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action. J Lipid Res 2006 47 537-552
12. Curb J D., Abbott R D., Rodriguez B L., et al. A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly. J Lipid Res 2004 45 948-953
13. Davidson M H., McKenney J M., Shear C L. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels. J Am Coll Cardiol 2006 48 1774-1781
14. de Grooth G J., Kuivenhoven J A., Stalenhoef A F., et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation 2002 105 2159-2165
15. Fogelman A M. When good cholesterol goes bad. Nat Med 2004 10 902-903
16. Forrest M J., Bloomfield D, Briscoe R J., et al. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br J Pharmacol 2008 154 1465-1473
17. Frick M H., Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987 317 1237-1245
18. Fruchart J C. Peroxisome proliferator-activated receptor-alpha activation and high-density lipoprotein metabolism. Am J Cardiol 2001 88 24N-29N
19. Gohlke H, Kubler W, Mathes P, et al. [Position paper on the primary prevention of cardiovascular diseases. Current position of the 25.3.2003 Statement of the Board of the German Society of Cardiology heart and circulatory research work commissioned by for the board by Project Group on Prevention]. Z Kardiol 2005 94 Suppl 2 III/113-115
20. Gordon T, Castelli W P., Hjortland M C., Kannel W B., Dawber T R. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977 62 707-714
21. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 2007 28 2375-2414
22. Hayek T, Masucci-Magoulas L, Jiang X, et al. Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene. J Clin Invest 1995 96 2071-2074
23. Hedrick C C., Thorpe S R., Fu M X., et al. Glycation impairs high-density lipoprotein function. Diabetologia 2000 43 312-320
24. Hirano K, Yamashita S, Nakajima N, et al. Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity. Arterioscler Thromb Vasc Biol 1997 17 1053-1059
25. Ishigami M, Yamashita S, Sakai N, et al. Large and cholesteryl ester-rich high-density lipoproteins in cholesteryl ester transfer protein (CETP) deficiency can not protect macrophages from cholesterol accumulation induced by acetylated low-density lipoproteins. J Biochem 1994 116 257-262
26. Kastelein J J., van Leuven S I., Burgess L, et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007 356 1620-1630
27. Krishna R, Anderson M S., Bergman A J., et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies. Lancet 2007 370 1907-1914
28. Manninen V, Elo M O., Frick M H., et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988 260 641-651 (Pubitemid 18183862)
29. Millar J S., Brousseau M E., Diffenderfer M R., et al. Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans. Arterioscler Thromb Vasc Biol 2006 26 1350-1356
30. Mineo C, Deguchi H, Griffin J H., Shaul P W. Endothelial and antithrombotic actions of HDL. Circ Res 2006 98 1352-1364
31. Navab M, Ananthramaiah G M., Reddy S T., et al. The double jeopardy of HDL. Ann Med 2005 37 173-178
32. Navab M, Hama S Y., Hough G P., et al. A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. J Lipid Res 2001 42 1308-1317
33. Negre-Salvayre A, Dousset N, Ferretti G, et al. Antioxidant and cytoprotective properties of high-density lipoproteins in vascular cells. Free Radic Biol Med 2006 41 1031-1040
34. Nissen S E., Tardif J C., Nicholls S J., et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007 356 1304-1316
35. Nissen S E., Tsunoda T, Tuzcu E M., et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003 290 2292-2300
36. Parhofer S. Handbuch der Fettstoffwechselstörungen. 3., vollständig überarbeitete und erweiterte Auflage. Schattauer Verlag
37. Plump A S., Masucci-Magoulas L, Bruce C, et al. Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression. Arterioscler Thromb Vasc Biol 1999 19 1105-1110
38. Robins S J., Collins D, Wittes J T., et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 2001 285 1585-1591
39. Rohrer L, Hersberger M, von Eckardstein A. High density lipoproteins in the intersection of diabetes mellitus, inflammation and cardiovascular disease. Curr Opin Lipidol 2004 15 269-278
40. Rubins H B., Robins S J., Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999 341 410-418
41. Sirtori C R., Fumagalli R. LDL-cholesterol lowering or HDL-cholesterol raising for cardiovascular prevention. A lesson from cholesterol turnover studies and others. Atherosclerosis 2006 186 1-11
42. Stein E A., Stroes E S., Steiner G, et al. Safety and tolerability of dalcetrapib. Am J Cardiol 2009 104 82-91
43. Thompson A, Di Angelantonio E, Sarwar N, et al. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA 2008 299 2777-2788
44. Zhong S, Sharp D S., Grove J S., et al. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest 1996 97 2917-2923
45. Forrester J S., Makkar R, Shah P K. Increasing high-density lipoprotein cholesterol in dyslipidemia by cholesteryl ester transfer protein inhibition: an update for clinicians. Circulation 2005 111 1847-1854